Cargando…

Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy

Chronic bacterial respiratory-tract infections are a major driving force in the pathogenesis of cystic fibrosis (CF) lung disease and promote chronic lung-function decline, destruction, and progression to respiratory failure at a premature age. Gram-negative bacteria colonizing the airways in CF are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koerner-Rettberg, Cordula, Ballmann, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4178503/ https://www.ncbi.nlm.nih.gov/pubmed/25278817 http://dx.doi.org/10.2147/CE.S64980

Ejemplares similares

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study
por: Schuster, Antje, et al.
Publicado: (2013)

High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study
por: Scheuing, Nicole, et al.
Publicado: (2014)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Reduced Lung Function in a Chronic Asthma Model Is Associated with Prolonged Inflammation, but Independent of Peribronchial Fibrosis
por: Koerner-Rettberg, Cordula, et al.
Publicado: (2008)

Barriers for Sports and Exercise Participation and Corresponding Barrier Management in Cystic Fibrosis
por: Dillenhoefer, Stefanie, et al.
Publicado: (2022)

Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium
por: Collie, David, et al.
Publicado: (2015)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Reversible Hypokalemia and Bartter-Like Syndrome during Prolonged Systemic Therapy with Colistimethate Sodium in an Adult Patient
por: Kamal Eldin, Tarek, et al.
Publicado: (2017)

Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by Pseudomonas aeruginosa: A Narrative Review of Current Evidence
por: de la Rosa-Carrillo, David, et al.
Publicado: (2022)

Association between habitual physical activity (HPA) and sleep quality in patients with cystic fibrosis
por: Dietz-Terjung, Sarah, et al.
Publicado: (2020)

Trainability of Health-Related and Motor Performance Fitness in Adults with Cystic Fibrosis within a 12-Month Partially Supervised Exercise Program
por: Welsner, Matthias, et al.
Publicado: (2021)

Effects of a Long-Term Monitored Exercise Program on Aerobic Fitness in a Small Group of Children with Cystic Fibrosis
por: Gruber, Wolfgang, et al.
Publicado: (2022)

Surfactant Protein A in Cystic Fibrosis: Supratrimeric Structure and Pulmonary Outcome
por: Griese, Matthias, et al.
Publicado: (2012)

A Novel Validated Injectable Colistimethate Sodium Analysis Combining Advanced Chemometrics and Design of Experiments
por: Dagla, Ioanna, et al.
Publicado: (2021)

Long-Term Follow-Up of Health-Related Quality of Life and Short-Term Intervention with CFTR Modulator Therapy in Adults with Cystic Fibrosis: Evaluation of Changes over Several Years with or without 33 Weeks of CFTR Modulator Therapy
por: Gruber, Wolfgang, et al.
Publicado: (2023)

Adverse Events and Drug Resistance in Critically Ill Patients Treated with Colistimethate Sodium: A Review of the Literature
por: Ahumada Topete, Victor Hugo, et al.
Publicado: (2023)

Interaction of Bacterial Phenazines with Colistimethate in Bronchial Epithelial Cells
por: Mossine, Valeri V., et al.
Publicado: (2018)

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
por: Margaritopoulos, George A, et al.
Publicado: (2016)

Factors Associated with Worse Lung Function in Cystic Fibrosis Patients with Persistent Staphylococcus aureus
por: Junge, Sibylle, et al.
Publicado: (2016)

Neutrophil Gelatinase-associated Lipocalin as a Predictor of Acute Kidney Injury in Patients during Treatment with Colistimethate Sodium
por: Park, So Yeon, et al.
Publicado: (2018)

Incidence of nephrotoxicity associated with intravenous colistimethate sodium administration for the treatment of multidrug-resistant gram-negative bacterial infections
por: Sadyrbaeva-Dolgova, Svetlana, et al.
Publicado: (2022)

Multi-drug resistant Pseudomonas aeruginosa keratitis and its effective treatment with topical colistimethate
por: Chatterjee, Samrat, et al.
Publicado: (2016)

Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients
por: Griese, Matthias, et al.
Publicado: (2005)

Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy
por: Connett, GJ
Publicado: (2019)

Prognostic Relevance of Hypoglycemia Following an Oral Glucose Challenge for Cystic Fibrosis–Related Diabetes
por: Radike, Kerstin, et al.
Publicado: (2011)

N-acetylcysteine suppresses colistimethate sodium-induced nephrotoxicity via activation of SOD2, eNOS, and MMP3 protein expressions
por: Ceylan, Bahadir, et al.
Publicado: (2018)

Pharmacokinetic Characteristics of Nebulized Colistimethate Sodium Using Two Different Types of Nebulizers in Critically Ill Patients with Ventilator-Associated Respiratory Infections
por: Kyriakoudi, Anna, et al.
Publicado: (2022)

Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy
por: Donaldson, Sahai, et al.
Publicado: (2020)

The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo
por: Beyer, Marc, et al.
Publicado: (2005)

Quality of life is associated with physical activity and fitness in cystic fibrosis
por: Hebestreit, Helge, et al.
Publicado: (2014)

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
por: O’Reilly, Ruth, et al.
Publicado: (2013)

Open randomised prospective comparative multi-centre intervention study of patients with cystic fibrosis and early diagnosed diabetes mellitus
por: Ballmann, Manfred, et al.
Publicado: (2014)

Diabetes in Cystic Fibrosis: Multicenter Screening Results Based on Current Guidelines
por: Scheuing, Nicole, et al.
Publicado: (2013)

Colistimethate Acidic Hydrolysis Revisited: Arrhenius Equation Modeling Using UPLC-QToF MS
por: Dagla, Ioanna, et al.
Publicado: (2021)

Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis
por: Atanasova, Kalina R., et al.
Publicado: (2018)

The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy
por: Lommatzsch, Sherstin T., et al.
Publicado: (2019)

Activated L-Arginine/Nitric Oxide Pathway in Pediatric Cystic Fibrosis and Its Association with Pancreatic Insufficiency, Liver Involvement and Nourishment: An Overview and New Results
por: Brinkmann, Folke, et al.
Publicado: (2020)

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum
por: Serisier, David J, et al.
Publicado: (2009)

The Microbiome in Cystic Fibrosis Pulmonary Disease
por: Françoise, Alice, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mqndj5ddc570eu5b60gper3i25